Literature DB >> 2496880

Antiviral treatment and postherpetic neuralgia.

P Klenerman, T E Peto, G A Luzzi, B E Juel-Jensen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2496880      PMCID： PMC1836058          DOI： 10.1136/bmj.298.6676.832

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

1.  Lack of effect of acyclovir on postherpetic neuralgia.

Authors:  M W McKendrick; J I McGill; M J Wood
Journal:  BMJ       Date:  1989-02-18

2.  Treatment of zoster with idoxuridine in dimethyl sulphoxide. Results of two double-blind controlled trials.

Authors:  B E Juel-Jensen; F O MacCallum; A M Mackenzie; M C Pike
Journal:  Br Med J       Date:  1970-12-26

3.  Early vidarabine therapy to control the complications of herpes zoster in immunosuppressed patients.

Authors:  R J Whitley; S J Soong; R Dolin; R Betts; C Linnemann; C A Alford
Journal:  N Engl J Med       Date:  1982-10-14       Impact factor: 91.245

Review 4.  Acyclovir in shingles.

Authors:  B Bean; D Aeppli; H H Balfour
Journal:  J Antimicrob Chemother       Date:  1983-09       Impact factor: 5.790
  4 in total
  4 in total

1.  Treatment of shingles and post-herpetic neuralgia.

Authors: 
Journal:  BMJ       Date:  1989-08-05

2.  Treatment of shingles and post-herpetic neuralgia.

Authors: 
Journal:  BMJ       Date:  1989-09-16

Review 3.  Pharmacologic management of herpes zoster and postherpetic neuralgia.

Authors:  F S Mamdani
Journal:  Can Fam Physician       Date:  1994-02       Impact factor: 3.275

4.  A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax.

Authors:  Larry I Gilderman; James F Lawless; Thomas M Nolen; Tina Sterling; Ruth Z Rutledge; Doreen A Fernsler; Neal Azrolan; Santosh C Sutradhar; William W Wang; Ivan S F Chan; Katia Schlienger; Florian Schödel; Jeffrey L Silber
Journal:  Clin Vaccine Immunol       Date:  2007-12-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.